Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
28 Marzo 2024 - 3:19PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for autoimmune diseases and cancer, today announced it
granted an inducement award on March 28, 2024.
One individual was hired by Adicet in March 2024 and granted new
hire non-qualified stock options to purchase 99,400 shares of
Adicet’s common stock with an exercise price of $2.35 per share,
the closing price of Adicet’s common stock as reported by Nasdaq on
March 28, 2024. One-fourth of the shares underlying the employee’s
option will vest on the one-year anniversary of the recipient’s
start date and thereafter the remaining three-fourths of the shares
underlying the employee’s option will vest in thirty-six
substantially equal monthly installments, such that the shares
underlying the option granted to the employee will be fully vested
on the fourth anniversary of the recipient’s start date, subject to
the employee’s continued employment with Adicet on such vesting
dates.
The above-described award was granted outside of Adicet’s
stockholder-approved equity incentive plans pursuant to Adicet’s
2022 Inducement Plan (the Inducement Plan), which was adopted by
the board of directors in January 2022 and subsequently amended in
January 2023. The award was authorized by the compensation
committee of the board of directors, which is comprised solely of
independent directors, as a material inducement to the employee
entering into employment with Adicet in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for autoimmune diseases and cancer. Adicet is advancing a pipeline
of “off-the-shelf” gamma delta T cells, engineered with chimeric
antigen receptors (CARs), to facilitate durable activity in
patients. For more information, please visit our website at
https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328981961/en/
Adicet Bio, Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Adicet Bio (NASDAQ:ACET)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024